Results
Overall, 47 reviews were eligible for inclusion. Out of the nine
COVID-19 outcomes evaluated, there was significant associations between
ACEIs/ARBs use and each of death (OR=0.80, 95%CI=0.75-0.86;
I2=51.9%), death/ICU admission as composite outcome
(OR=0.86, 95%CI=0.80-0.92; I2=43.9%), severe
COVID-19 (OR=0.86, 95%CI=0.78-0.95; I2=68%), and
hospitalisation (OR=1.23, 95%CI=1.04-1.46; I2=
76.4%). The significant reduction in death/ICU admission, however, was
higher among studies which presented adjusted measure of effects
(OR=0.63, 95%CI=0.47-0.84) and were of moderate quality (OR=0.74,
95%CI=0.63-0.85). There was no evidence of any significant association
between ACEIs, or ARBs and COVID-19 outcomes.